Pharmaceuticals, Biotechnology and Life Sciences
Santhera Pharmaceuticals has enrolled first DMD patients with respiratory function decline not taking glucocorticoids into UK’s Early Access to Medicines…
The pivotal Phase 3 Libery ASthma Quest study of dupilumab in a broad population of patients with uncontrolled, persistent asthma…
Targovax ASA, a clinical stage company focused on immuno-oncology therapies against solid tumors, on Monday revealed that three posters were…
India-based Piramal Pharma Solutions (PPS), part of Piramal Enterprises Limited, has named John Fowler as its Chief Operating Officer. In announcing…
Bristol-Myers Squibb has completed its previously announced acquisition of IFM Therapeutics, the company said on Thursday.
Sanofi and Regeneron Pharmaceuticals, said on Friday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to…
USA-based clinical-stage biotechnology company Pfenex Inc. is saying goodbye to its Chief Financial Officer, Dr. Paul Wagner, who has been said on…
Novartis’s AMG 334 (erenumab) for migraine prevention in a second phase study reduced monthly migraine days in patients with chronic…
Top-line results from the AstraZeneca’s Phase III AMPLIFY trial for Duaklir met its primary endpoints, demonstrating a statistically-significant improvement in lung function in patients with moderate to very severe stable chronic obstructive pulmonary disease (COPD) compared to each individual component, the company said Thursday. In addition, aclidinium bromide achieved its primary bronchodilation endpoint of demonstrating non-inferiority to tiotropium bromide 18µg once-daily.
AstraZeneca and Amgen on Thursday published results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation rate compared with placebo in patients with severe, uncontrolled asthma. The trial results were published in the New England Journal of Medicine. The PATHWAY trial achieved its primary efficacy endpoint, showing annual asthma exacerbation rate reductions.